GLP-1 receptor agonists are not a magic solution
The involvement of PLC- in OA-stimulated PI hydrolysis was examined using PLC- siRNA
Over one-quarter of new GLP-1 receptor agonist users in 2023 had no diabetes, according to a new study of US prescription trends published in Annals of Internal Medicine
10.1016/S2213-8587(19)30422-X Summary Keywords GLP-1 receptor agonists, diabetes, coronary artery disease, acute and chronic coronary syndromes, atherosclerosis, coronary microcirculation Citation Pahud de Mortanges A, Sinaci E, Salvador Jr D, Bally L, Muka T, Wilhelm M and Bano A (2022) GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
doi: 10.1186/s12903-020-01180-w 9 LiccardoDCannavoASpagnuoloGFerraraNCittadiniARengoCet al
John Gabe Horneff, an orthopedic surgeon at Pennsylvania Hospital, had noticed a peculiar trend: Some patients taking GLP-1s would come in with significant tendon injuries from relatively minor physical excursion